$ALGS
Aligos Therapeutics Inc
PRICE
$1.16 ▲3.509%
Last Close
VOLUME
31,242
DAY RANGE
1.1 - 1.19
52 WEEK
0.8401 - 2.41
Key Metrics
Market Cap
47.02 M
Beta
0.90
Avg. Volume
437.30 K
Shares Outstanding
39.85 M
Yield
0%
Public Float
0
Next Earnings Date
2023-08-03
Next Dividend Date
Company Information
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
Website: aligos.com
HQ: ,
Related News